Letter: Duration of action of beta-adrenergic blocking drugs

Besterman, E; McCarthy, C
July 1974
British Medical Journal;7/27/1974, Vol. 3 Issue 5925, p257
Academic Journal
No abstract available.


Related Articles

  • Comparison of antianginal actions of verapamil and propranolol. Bowles, M.J.; Subramanian, V. Bala; Davies, A.B.; Raftery, E.B. // British Medical Journal (Clinical Research Edition);5/30/1981, Vol. 282 Issue 6278, p1754 

    Compares antianginal actions of verapamil with propralonol, a standard beta-adrenergic receptor-blocking drug in patients with chronic stable angina in Great Britain. Side-effects of the drugs; Occurrence of constipation with verapamil; Decrease in the number of anginal attacks.

  • Reduced respiratory responses to carbon dioxide after propranolol. Mustchin, C.P.; Gribbin, H.R.; Tattersfield, A.E.; George, C.F. // British Medical Journal;11/20/1976, Vol. 2 Issue 6046, p1229 

    Examines the respiratory responses to carbon dioxide after propranolol. Reductions in respiratory sensitivity; Effects of beta-adrenergic blocking drugs on asthmatic patients; Stimulation of beta-adrenergic receptors.

  • Fifty years of beta-blockers: a revolution in CV pharmacotherapy. Frishman, William H. // Cardiology Today;Dec2008, Vol. 11 Issue 12, p18 

    The article talks about the revolution of beta-adrenergic receptor blocking drugs in cardiovascular (CV) pharmacotherapy for 50 years. It says that the development and clinical application of beta-blockers has provided one of the major advances in human pharmacotherapy. It states that the...

  • Advantages and Disadvantages of Beta- Adrenergic Blocking Drugs in Hypertension. O'Brien, Eoin T. // Angiology;Apr1978, Vol. 29 Issue 4, p332 

    This paper reviews the role of beta-adrenergic blocking drugs in the treatment of hypertension. A significant proportion of patients presenting with mild or moderate hypertension will respond to general measures and do not require specific drug therapy. Of the remaining patients, some will...

  • Diseases of the cardiovascular system: Drugs affecting the cardiovascular system: pharmacological basis of treatment.  // British Medical Journal;7/3/1976, Vol. 2 Issue 6026, p31 

    Focuses on drugs affecting the cardiovascular system. Efficacy of cardiac glycosides; Mechanism of therapeutic action of antiarrthymic drugs; Therapeutic effect of beta-adrenergic antagonists.

  • Treatment of migraine.  // Nutrition Health Review: The Consumer's Medical Journal;1994, Issue 70, p3 

    Presents several drugs used for treatment of migraine. Analgesics; Ergotamine, sumatriptan and clonidine for severe episodes; Beta-adrenergic blocking agents; Serotonin inhibitors.

  • Arrhythmia in hypertrophic cardiomyopathy.  // British Medical Journal;10/18/1980, Vol. 281 Issue 6247, p1026 

    Examines the occurrence of arrythmia in patients with hypertrophic cardiopathy. Response of patients to beta-adrenergic blocking drugs; Identification on the causes of death; Evidence of ventricular tachycardia.

  • Recurrent Ventricular Tachycardia and Fibrillation Treated with a Combination of Beta--Adrenergic Blockade and Electrical Pacing.  // Annals of Internal Medicine;May67, Vol. 66 Issue 5, p946 

    Describes the treatment of recurrent paroxysmal ventricular tachycardia and ventricular fibrillation with a combination of a beta-adrenergic blocking agent and electrical pacing in a girl without heart disease. Health benefits of beta-adrenergic blocking drugs; Extensive function of cardiac...

  • Hyperpigmentation associated with oxprenolol administration. Harrower, A.D.B.; Strong, J.A. // British Medical Journal;7/30/1977, Vol. 2 Issue 6082, p296 

    Examines the association between skin hyperpigmentation and oxprenolol administration. Occurrence of skin sensitivity reactions to beta-adrenergic receptor blocking drugs; characteristics of skin allergies; Regression of hyperpigmentation after drug withdrawals.

  • Beta blocker for hypertension.  // Modern Medicine;Nov95, Vol. 63 Issue 11, p35 

    Reports on the drug carvedilol, a beta-adrenergic blocking agent, which is used for hypertension and the clearance it received from the Food and Drug Administration (FDA). How the tablets can be taken.


Read the Article

Other Topics